Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: A single-centre, phase 2 study
Elias Jabbour, Hagop Kantarjian, Farhad Ravandi, Deborah Thomas, Xuelin Huang, Stefan Faderl, Naveen Pemmaraju, Naval Daver, Guillermo Garcia-Manero, Koji Sasaki, Jorge Cortes, Rebecca Garris, C. Cameron Yin, Joseph D. Khoury, Jeffrey Jorgensen, Zeev Estrov, Zachary Bohannan, Marina Konopleva, Tapan Kadia, Nitin JainCourtney DiNardo, William Wierda, Vicky Jeanis, Susan O'Brien
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: A single-centre, phase 2 study'. Together they form a unique fingerprint.